Navigation Links
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
Date:10/27/2011

of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

ADASUVE (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a Complete Response Letter from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011 and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The ADASUVE NDA will be presented to an advisory committee on December 12, 2011.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer International, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.  

For mo
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... CHICAGO, Ill. , July 23, 2014 ... OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ... OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. ... second-quarter 2014 financial results on Friday, July 25, 2014, before ... webcast of the earnings conference call at 8 a.m. Central ...
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid ... Network-Quality Improvement Organization (QIN-QIO) contract to a partnership led ... Effective August 1, WVMI will launch Quality Insights Quality ... Pennsylvania , Delaware ... The Network will engage providers and the community in ...
(Date:7/23/2014)... 2014 Research and Markets   ... Electrophysiology Ablation Catheters Market 2014-2018" report to ... Catheter ablation is a minimally ... electrical pathways from sections of the heart that ... arrhythmias). Cardiac arrhythmias can be of several types, ...
Breaking Medicine Technology:AbbVie to Host Second-Quarter Earnings Conference Call 2AbbVie to Host Second-Quarter Earnings Conference Call 3AbbVie to Host Second-Quarter Earnings Conference Call 4AbbVie to Host Second-Quarter Earnings Conference Call 5AbbVie to Host Second-Quarter Earnings Conference Call 6Announcing a New Regional Approach to Medicare Quality Improvement 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3
... Truphatek has successfully enticed one of the best known professionals in ... , Dan White , formerly of ... a new US subsidiary of Truphatek http://www.truphatek.com/ ... I may be reached after this week at 573-240-0002 or by e-mail ...
... , NEWARK, Calif., Oct. 6 Extending its reach ... North America, Inc. has signed ... distribute its perfluoroelastomer sealing components and provide local applications ... are integral in the ultraclean manufacturing of semiconductors, solar ...
Cached Medicine Technology:New Places and People - Truphatek opens USA subsidiary 2New Places and People - Truphatek opens USA subsidiary 3Applied Seals North America Extends Global Network With Addition of Distributor in Europe 2
(Date:7/23/2014)... Dallas, TX (PRWEB) July 23, 2014 ... could be diminished using non-surgical techniques, according to a ... of puffy eyes serum sold in the U.S. is ... http://cherrynews.com/best-nourishing-eye-serum . , The complimentary guide that is ... consumers who struggle with under eye puffiness. While surgical ...
(Date:7/23/2014)... near Sellafield or Dounreay since the 1990s are not ... research published in the British Journal of Cancer ... Research Group at the University of Oxford and from ... among those who were under 25 and living near ... in cancer incidence from 1991-2006 between those living near ...
(Date:7/23/2014)... Oklahoma (PRWEB) July 23, 2014 ... America’s leading provider of in-home care for seniors, ... Longevity Webinar Series featuring experts in a wide ... webinar will feature licensed clinical social worker and ... most common causes of caregiver stress and ways ...
(Date:7/23/2014)... 2014 In preparation for National Health ... Treatment Group is providing tips on choosing a reputable ... ever since man first figured out the process of ... existed since shortly thereafter. Its basis lies in the ... developing a way to combat that problem while monetizing ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July 23, 2014 (HealthDay ... exposed to some form of childhood trauma than their civilian ... to apply solely to military men, not women. The ... for concern, given that early childhood exposure to various forms ... has been linked to a higher adult risk for depression, ...
Breaking Medicine News(10 mins):Health News:Puffy Eyes Serum Explored in Complimentary Guide Released at Consumer News Website 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 3Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 2Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 3
... cancer is the most common cancer diagnosed among men in ... There are several // treatment options, but new research shows ... , Doctors hope that the drug -- finasteride ... smaller doses, it’s commonly known as Propecia for baldness. It ...
... A new study finds angioplasty should be the treatment ... hospital they initially go to doesn’t offer angioplasty// services ... for treatment. ,Research has shown heart attack patients ... open up the clogged blood vessel that caused the ...
... New research reports, patients who were treated for depression ... vitamin B12 in their blood.// ,An increasing amount ... B and depression, but the specifics have not been ... relationship of vitamin B12 and the treatment of depression. ...
... A new study shows people who suffer from migraine headaches ... which are areas of the brain where the tissue has ... ages 30 to 60. They grouped the patients into categories ... no visual difficulties. A control group was also included in ...
... new study finds people who participated in a cardiac-rehab program ... rate // as those of the same age and sex ... about half of the deaths that occurred among patients in ... cardiac-rehab program. ,The investigation involved about 1,800 patients. Nearly ...
... from extremely low body fat whether due to strenuous ... from treatment with the appetite-and-weight-regulation hormone leptin.// The study ... instances of infertility. ,Leptin is produced in fat ... then travels to the brain and plays a role ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: